Cited by 942Cytokine Signaling Pathways and InteractionsImmunodeficiency and Autoimmune DisordersNF-κB Signaling Pathways

The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

Open access

O'Shea, John J., Holland, Steven M., Staudt, Louis M.·2013·New England Journal of Medicine

DOI 10.1056/nejmra1202117PMC PMC7604876

Open this paper in CoChat — free account

Abstract

A large number of cytokines signal through the JAK–STAT pathway. Abnormal function of this pathway may lead to a variety of diseases. Targeting the defects in this signaling pathway has already led to treatment advances, and further advances are likely.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmra1202117

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAKS AND STATS: Biological Implications
Leonard, W. J., & O’Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,826
Self-citation
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596

Show all 101 references

Research works printed but not linked: 1

10.1172/JCI0215617 · DOI

Sorted by citations

Items 201–300 of 942

PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma
Gao, Y., Luo, L., Xie, Y., Zhao, Y., Yao, J., & Liu, X. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23174 · Cited by 56
Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential
Kuriya, B., Cohen, M. D., & Keystone, E. (2017) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16687481 · Cited by 55
Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type
Sim, S. H., Kim, S., Kim, T. M., Jeon, Y. K., Nam, S. J., Ahn, Y., Keam, B., Park, H. H., Kim, D., Kim, C. W., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.01.004 · Cited by 55
Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
Harigai, M., Takeuchi, T., Smolen, J. S., Winthrop, K. L., Nishikawa, A., Rooney, T. P., Saifan, C., Issa, M., Isaka, Y., Akashi, N., et al. (2019) · Modern Rheumatology · doi:10.1080/14397595.2019.1583711 · Cited by 55
The Caenorhabditis elegans Protein FIC-1 Is an AMPylase That Covalently Modifies Heat-Shock 70 Family Proteins, Translation Elongation Factors and Histones
Truttmann, M. C., Cruz, V. E., Guō, X., Engert, C., Schwartz, T., & Ploegh, H. L. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006023 · Cited by 50
Loss of JAK1 Drives Innate Immune Deficiency
Witalisz‐Siepracka, A., Klein, K., Prinz, D., Leidenfrost, N., Schabbauer, G., Dohnal, A. M., & Sexl, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03108 · Cited by 54
Novel targets in the treatment of chronic graft-versus-host disease
Im, A., Hakim, F. T., & Pavletic, S. Z. (2016) · Leukemia · doi:10.1038/leu.2016.367 · Cited by 54
Targeting cytokine signaling in autoimmunity: back to the future and beyond
Hirahara, K., Schwartz, D. M., Gadina, M., Kanno, Y., & O’Shea, J. J. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.10.001 · Cited by 53
Self-citation
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
Emery, P., Blanco, R., Cocco, J. M., Chen, Y., Gaich, C. L., DeLozier, A. M., de Bono, S., Liu, J., Rooney, T. P., Chang, C. H.-C., et al. (2017) · RMD Open · doi:10.1136/rmdopen-2016-000410 · Cited by 53
Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia
Kollmann, S., Grundschober, E., Maurer, B., Warsch, W., Grausenburger, R., Edlinger, L., Huuhtanen, J., Lagger, S., Hennighausen, L. G., Valent, P., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0369-5 · Cited by 53
Gastrodin Inhibits Inflammasome Through the STAT3 Signal Pathways in TNA2 Astrocytes and Reactive Astrocytes in Experimentally Induced Cerebral Ischemia in Rats
Sui, Y., Bian, L., Ai, Q., Yao, Y., Yu, M., Gao, H., Zhang, A., Fu, X., Zhong, L., & Lü, D. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08544-8 · Cited by 52
STAT Transcription Factors in T Cell Control of Health and Disease
Goswami, R., & Kaplan, M. H. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.012 · Cited by 52
Combined inhibition of JAK1,2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia
Xu, L.-J., Ma, Q., Zhu, J., Li, J., Xue, B., Gao, J., Sun, C.-Y., Zang, Y.-C., Zhou, Y.-B., Yang, D.-R., et al. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8905 · Cited by 51
Traditional Chinese Medicine and Natural Products: Potential Approaches for Inflammatory Bowel Disease
Yuan, S., Li, Y., Li, J., Xue, J.-C., Wang, Q., Hou, X.-T., Meng, H., Nan, J., & Zhang, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.892790 · Cited by 52
AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis
Li, C., Zhao, J., Sun, L., Yao, Z., Deng, X., Liu, R., & Liu, X. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.084 · Cited by 52
Givinostat: an emerging treatment for polycythemia vera
Chifotides, H. T., Bose, P., & Verstovšek, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1761323 · Cited by 51
Non-CSCs nourish CSCs through interleukin-17E-mediated activation of NF-κB and JAK/STAT3 signaling in human hepatocellular carcinoma
Luo, Y., Yang, Z., Su, L., Shan, J., Xu, H., Xu, Y., Liu, L., Zhu, W., Chen, X., Liu, C., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.012 · Cited by 50
Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study
Rosas, J., Liaño, F. P., Llombart, M., Barea, J. M. C., Beser, A. R., Rabasa, J. T. A., Martínez-Adsuar, F., Auli, B. V., López, I. F., Sainz, A. M. G., et al. (2020) · Reumatología Clínica · doi:10.1016/j.reuma.2020.10.009 · Cited by 49
Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis
MacFarlane, L. A., & Todd, D. J. (2014) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.12293 · Cited by 49
Tofacitinib for the treatment of moderate-to-severe psoriasis
Chiricozzi, A., Faleri, S., Saraceno, R., Bianchi, L., Buonomo, O. C., Chimenti, S., & Chimenti, M. S. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1013534 · Cited by 50
Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders
Puleo, D. E., Kucera, K., Hammarén, H. M., Ungureanu, D., Newton, A. S., Silvennoinen, O., Jorgensen, W. L., & Schlessinger, J. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00153 · Cited by 48
Oncolytic Virotherapy Blockade by Microglia and Macrophages Requires STAT1/3
Delwar, Z. M., Kuo, Y., Wen, Y. H., Rennie, P. S., & Jia, W. W.-G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0599 · Cited by 49
Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action
Storr, H. L., Chatterjee, S., Metherell, L., Foley, C. L., Rosenfeld, R. G., Backeljauw, P. F., Dauber, A. N., Savage, M. O., & Hwa, V. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00146 · Cited by 50
Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis
Kotyla, P. J., Islam, M. A., & Engelmann, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197390 · Cited by 49
A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal
Chen, C., Yin, Y., Shi, G., Zhou, Y. J., Shao, S., Wei, Y., Wu, L., Zhang, D., Sun, L., & Zhang, T. (2022) · Science Advances · doi:10.1126/sciadv.abo4363 · Cited by 51
Cancer cachexia: molecular basis and therapeutic advances
Tan, Y., Xue, R., Pan, Y., he, Z., Hu, X., Li, Y., Li, K., Zhang, X., Bian, X.-W., & Wang, B. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02331-7 · Cited by 57
Tyrosine phosphorylation of HuR by JAK3 triggers dissociation and degradation of HuR target mRNAs
Yoon, J., Abdelmohsen, K., Srikantan, S., Guo, R., Yang, X., Martindale, J. L., & Gorospe, M. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt903 · Cited by 49
Hyaluronic acid-coated proglycosomes for topical delivery of tofacitinib in rheumatoid arthritis condition: Formulation design, in vitro, ex vivo characterization, and in vivo efficacy studies
Gorantla, S., Puppala, E. R., Naidu, V. G. M., Saha, R. N., & Singhvi, G. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.117 · Cited by 47
The ups and downs of STAT3 function: too much, too little and human immune dysregulation
Mackie, J., Ma, C. S., Tangye, S. G., & Guérin, A. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad007 · Cited by 47
STAT3 regulated ATR via microRNA-383 to control DNA damage to affect apoptosis in A431 cells
Liao, X., Zheng, L., He, H., Zheng, D., Wei, Z., Wang, N., Dong, J., Ma, W., & Zhang, T. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.08.005 · Cited by 48
Cell Signaling Pathways That Regulate Antigen Presentation
Brutkiewicz, R. R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600460 · Cited by 48
Are Janus kinase inhibitors superior over classic biologic agents in RA patients?
Kotyla, P. J. (2018) · BioMed Research International · doi:10.1155/2018/7492904 · Cited by 47
Classical and novel GH receptor signaling pathways
Frank, S. J. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110999 · Cited by 46
Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers
Ni, Y., Low, J. T., Silke, J., & O’Reilly, L. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835997 · Cited by 47
The Th17/IL-17 Axis and Host Defense Against Fungal Infections
Tangye, S. G., & Puel, A. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.04.015 · Cited by 50
Small molecule drug discovery targeting the JAK-STAT pathway
Lv, Y., Mi, P., Babon, J. J., Fan, G.-H., Qi, J., Cao, L., Lang, J., Zhang, J., Wang, F., & Kobe, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107217 · Cited by 48
HypE-specific Nanobodies as Tools to Modulate HypE-mediated Target AMPylation
Truttmann, M. C., Wu, Q., Stiegeler, S., Duarte, J. N., Ingram, J. R., & Ploegh, H. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.634287 · Cited by 46
Altered glycolipid and glycerophospholipid signaling drive inflammatory cascades in adrenomyeloneuropathy
Ruíz, M., Jové, M., Schlüter, A., Casasnovas, C., Villarroya, F., Guilera, C., Ortega, F. J., Naudí, A., Pamplona, R., Gimeno, R., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv375 · Cited by 46
Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study
Peeva, E., Hodge, M. R., Kieras, E., Vazquez, M. L., Goteti, K., Tarabar, S., Alvey, C. W., & Banfield, C. R. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13612 · Cited by 45
Ganoderic acid A exerts antitumor activity against MDA‑MB‑231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway
Yang, Y., Zhou, H., Liu, W., Wu, J., Yue, X., Wang, J., Quan, L., Liu, H., Guo, L., Wang, Z., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.9475 · Cited by 45
KDM3A histone demethylase functions as an essential factor for activation of JAK2−STAT3 signaling pathway
Kim, H.-K., Kim, D., Choi, S. A., Kim, C. R., Oh, S. K., Pyo, K. E., Kim, J., Lee, S., Yoon, J., Zhang, Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805662115 · Cited by 45
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
King, B., Maari, C., Lain, E. L., Silverberg, J. I., Issa, M., Holzwarth, K., Brinker, D. R., Cardillo, T. E., Nunes, F. P., & Simpson, E. L. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00602-x · Cited by 45
Short Stature in a Boy with Multiple Early-Onset Autoimmune Conditions due to a STAT3 Activating Mutation: Could Intracellular Growth Hormone Signalling Be Compromised?
Šedivá, H., Dušátková, P., Kanderová, V., Obermannová, B., Kayserová, J., Šrámková, L., Zemkova, D., Elblová, L., Svaton, M., Zachová, R., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000456544 · Cited by 44
Frontiers in Drug Research and Development for Inflammatory Bowel Disease
Currò, D., Pugliese, D., & Armuzzi, A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00400 · Cited by 44
Upregulated expression of STAT3/IL-17 in patients with systemic lupus erythematosus
Chen, S., Liu, M.-F., Kuo, P., & Wang, C. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04467-8 · Cited by 45
Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment
Deng, S., Clowers, M. J., Velasco, W. V., Ramos-Castaneda, M. A., & Moghaddam, S. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01556 · Cited by 45
Primary immunodeficiency disorders: general classification, new molecular insights, and practical approach to diagnosis and treatment
Ochs, H. D., & Hagin, D. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.04.007 · Cited by 43
Vitamin D Deficiency in a Multiethnic Healthy Control Cohort and Altered Immune Response in Vitamin D Deficient European-American Healthy Controls
Ritterhouse, L. L., Lu, R., Shah, H. B., Robertson, J. M., Fife, D. A., Maecker, H. T., Du, H., Fathman, C. G., Chakravarty, E. F., Scofield, R. H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094500 · Cited by 42
JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs
Cornez, I., Yajnanarayana, S. P., Wolf, A. M., & Wolf, D. G. F. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.035 · Cited by 43
Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation
Bitar, M., Boldt, A., Freitag, M.-T., Gruhn, B., Koehl, U., & Sack, U. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00722 · Cited by 43
JAK inhibitors in 2019, synthetic review in 10 points
Muller, R. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.05.022 · Cited by 43
Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)
Verweyen, E. L., & Schulert, G. S. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab673 · Cited by 43
TYK2 Promoter Variant and Diabetes Mellitus in the Japanese
Nagafuchi, S., Hibio, Y., Hirakawa, K., Tsutsu, N., Minami, M., Okada, A., Kai, K., Teshima, M., Moroishi, A., Murakami, Y., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.05.004 · Cited by 43
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis
Bannwarth, B., Kostine, M., & Poursac, N. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.789500 · Cited by 42
Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy
Vick, E. J., Patel, K., Prouet, P., & Martin, M. G. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017005561 · Cited by 42
Common gamma chain cytokines and CD8 T cells in cancer
Shourian, M., Beltra, J., Bourdin, B., & Decaluwe, H. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101307 · Cited by 43
STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation
Kim, D., Park, G., Huuhtanen, J., Ghimire, B. R., Rajala, H. L. M., Moriggl, R., Chan, W. C., Kankainen, M., Myllymäki, M., & Mustjoki, S. M. (2021) · Leukemia · doi:10.1038/s41375-021-01296-0 · Cited by 43
ALOX5 drives the pyroptosis of CD4 + T cells and tissue inflammation in rheumatoid arthritis
Cai, H., Zhang, J., Xu, H., Sun, W., Wu, W., Dong, C., Zhou, P., Xue, C., Nan, Y., Ni, Y., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adh1178 · Cited by 42
Hepatitis B virus reactivation associated with ruxolitinib
Shen, C., Hwang, C.-E., Chen, Y., & Chen, C. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1936-5 · Cited by 41
Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases
Liu, Y., Gibson, S. A., Benveniste, E. N., & Qin, H. (2015) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2016015517 · Cited by 43
Temporal retinal transcriptome and systems biology analysis identifies key pathways and hub genes in Staphylococcus aureus endophthalmitis
Rajamani, D., Singh, P. K., Rottmann, B. G., Singh, N., Bhasin, M., & Kumar, A. (2016) · Scientific Reports · doi:10.1038/srep21502 · Cited by 43
JAK inhibition in the treatment of alopecia areata – a promising new dawn?
Ismail, F. F., & Sinclair, R. D. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1702878 · Cited by 41
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
Gurule, N. J., McCoach, C. E., Hinz, T. K., Merrick, D. T., Bokhoven, A. V., Kim, J., Patil, T., Calhoun, J., Nemenoff, R. A., Tan, A. C., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00181-4 · Cited by 39
Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression
Zhang, C., Ma, H., Wu, S., Shen, J., Zhang, N., Xu, Y., Li, C.-X., He, P., Ge, M.-K., Chu, X., et al. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.08.003 · Cited by 42
Evolutionarily conserved transcription factors as regulators of longevity and targets for geroprotection
Fischer, F., Grigolon, G., Benner, C., & Ristow, M. (2022) · Physiological Reviews · doi:10.1152/physrev.00017.2021 · Cited by 42
Editorial: Decernotinib: A Next‐Generation Jakinib
Gadina, M., Schwartz, D. M., & O’Shea, J. J. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39463 · Cited by 40
Self-citation
SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance
Li, J., Wu, R., Yung, M. M. H., Sun, J., Li, Z., Yang, H., Zhang, Y., Liu, S. S., Cheung, A., Ngan, H., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03635-6 · Cited by 39
Small molecules targeting cGAS-STING pathway for autoimmune disease
Zhao, J., Xiao, R., Zeng, R., He, E., & Zhang, A. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114480 · Cited by 40
Regulation mechanism of curcumin mediated inflammatory pathway and its clinical application: a review
Liu, M., Wang, J., Song, Z., & Pei, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1642248 · Cited by 39
Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis
He, C., Yu, C., Sun, L., Mahdi, R. M., Larkin, J., & Egwuagu, C. E. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.05.011 · Cited by 39
Signal transducer and activator of transcription gain-of-function primary immunodeficiency/immunodysregulation disorders
Consonni, F., Dotta, L., Todaro, F., Vairo, D., & Badolato, R. (2017) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000551 · Cited by 38
Polycystic Kidney Disease and Renal Fibrosis
Xue, C., & Mei, C. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_5 · Cited by 38
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
Tarrant, J. M., Galien, R., Li, W., Goyal, L., Pan, Y., Hawtin, R. E., Zhang, W., der Aa, A. V., & Taylor, P. C. (2020) · Rheumatology and Therapy · doi:10.1007/s40744-019-00192-5 · Cited by 38
Primary mediastinal lymphoma: diagnosis and treatment options
Martelli, M., Rocco, A. D., Russo, E., Perrone, S., & Foà, R. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2015.994604 · Cited by 37
Treatment options for chronic mucocutaneous candidiasis
van de Veerdonk, F. L., & Netea, M. G. (2016) · Journal of Infection · doi:10.1016/j.jinf.2016.04.023 · Cited by 37
Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies
Bruserud, Ø., Aasebø, E., Hernandez-Valladares, M., Tsykunova, G., & Reikvam, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356818 · Cited by 38
A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions
Lin, T. E., HuangFu, W., Chao, M., Sung, T.-Y., Chang, C.-D., Chen, Y.-Y., Hsieh, J., Tu, H., Huang, H.-L., Pan, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01379 · Cited by 39
TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
Jo, C. E., Gooderham, M., & Beecker, J. R. (2021) · International Journal of Dermatology · doi:10.1111/ijd.15605 · Cited by 36
Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System
Dong, Z., Ye, X., Chen, C., Wang, R., Liu, D., Xu, X., Zhou, X., & He, J. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15361 · Cited by 37
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
Senkevitch, E., & Durum, S. K. (2016) · Cytokine · doi:10.1016/j.cyto.2016.10.012 · Cited by 38
Using Drosophila melanogaster as a suitable platform for drug discovery from natural products in inflammatory bowel disease
Xiu, M., Wang, Y., Yang, D., Zhang, X., Dai, Y., Liu, Y., Lin, X., Li, B., & He, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072715 · Cited by 36
Molecular biology of human epidermal receptors, signaling pathways and targeted therapy against cancers: new evidences and old challenges
Ferreira, P. M. P., & Pessoa, C. (2017) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902017000216076 · Cited by 36
STAT signaling in polycystic kidney disease
Strubl, S., Torres, J. A., Spindt, A. K., Pellegrini, H., Liebau, M. C., & Weimbs, T. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109639 · Cited by 35
JAK inhibition as a new treatment strategy for patients with COVID-19
Huang, J., Zhou, C., Jinniu, D., & Zhou, J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115162 · Cited by 36
Glutamine Deficiency Promotes PCV2 Infection through Induction of Autophagy via Activation of ROS-Mediated JAK2/STAT3 Signaling Pathway
Liu, D., Lin, J., Su, J., Chen, X., Jiang, P., & Huang, K. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b04704 · Cited by 36
Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs
Kim, B., Won, C., Lee, Y.-H., Choi, J. S., Noh, K. H., Han, S., Lee, H., Lee, C. S., Lee, D., Ye, S., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.009 · Cited by 35
New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes
Bezzerri, V., Vella, A., Calcaterra, E., Finotti, A., Gasparello, J., Gambari, R., Assael, B. M., Cipolli, M., & Sorio, C. (2016) · Scientific Reports · doi:10.1038/srep33165 · Cited by 37
Liquid chromatographic-tandem mass spectrometric assay for simultaneous quantitation of tofacitinib, cabozantinib and afatinib in human plasma and urine
Kadi, A. A., Abdelhameed, A. S., Darwish, H. W., Attwa, M. W., & Bakheit, A. H. H. (2017) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v15i12.21 · Cited by 35
Cytokine Signaling Protein 3 Deficiency in Myeloid Cells Promotes Retinal Degeneration and Angiogenesis through Arginase-1 Up-Regulation in Experimental Autoimmune Uveoretinitis
Chen, M., Zhao, J., Ali, I. H. A., Marry, S., Augustine, J., Bhuckory, M. B., Lynch, A., Kissenpfennig, A., & Xu, H. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.12.021 · Cited by 34
Between‐population differences in constitutive and infection‐induced gene expression in threespine stickleback
Fuess, L. E., Weber, J. N., den Haan, S., Steinel, N. C., Shim, K. C., & Bolnick, D. I. (2021) · Molecular Ecology · doi:10.1111/mec.16197 · Cited by 35
Transcriptional regulation of effector and memory CD8+ T cell fates
Thaventhiran, J. E. D., Fearon, D. T., & Gattinoni, L. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.05.010 · Cited by 33
A new role for STAT3 as a regulator of chromatin topology
Zhao, Y., Zeng, C., Tarasova, N. I., Chasovskikh, S., Dritschilo, A., & Timofeeva, O. A. (2013) · Transcription · doi:10.4161/trns.27368 · Cited by 35
Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome
Mori, M., Morio, T., Ito, S., Morimoto, A., Ota, S., Mizuta, K., Iwata, T., Hara, T., & Saji, T. (2014) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2014.05.001 · Cited by 34
Cytokine-Mediated Regulation of Human Lymphocyte Development and Function: Insights from Primary Immunodeficiencies
Tangye, S. G., Pelham, S. J., Deenick, E. K., & Ma, C. S. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700842 · Cited by 34
STAT5 is activated in macrophages by breast cancer cell-derived factors and regulates macrophage function in the tumor microenvironment
Jesser, E. A., Brady, N. J., Huggins, D. N., Witschen, P. M., O’Connor, C. H., & Schwertfeger, K. L. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01481-0 · Cited by 34
Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
Gou, P., Zhang, W., & Giraudier, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031013 · Cited by 34
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1
Kettle, J. G., Åstrand, A., Catley, M. C., Grimster, N. P., Nilsson, M., Su, Q., & Woessner, R. D. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1252753 · Cited by 34
miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia
Navarro, A., Pairet, S., Álvarez‐Larrán, A., Pons, A., Ferrer, G., Longarón, R., Fernández‐Rodríguez, C., Camacho, L., Monzó, M., Besses, C., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.10 · Cited by 33
STAT gene family mRNA expression and prognostic value in hepatocellular carcinoma
Dong, Z., Chen, Y., Yang, C. Z., Zhang, M., Chen, A., Yang, J., & Huang, Y. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s202122 · Cited by 33
A novel treatment for psoriatic arthritis: Janus kinase inhibitors
Chen, M., & Dai, S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000711 · Cited by 33

Authors: O'Shea, J. J., Holland, S. M., & Staudt, L. M.
Affiliations: National Institute of Allergy and Infectious Diseases (US)
National Institutes of Health (US)
ORCID: Holland, Steven M.
Staudt, Louis M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-01-10
Volume: 368
Issue: 2
Pages: 161-170
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra1202117
PMC: PMC7604876
OpenAlex: W2040002852
Cited by: 927
References: 101
Citations by year: 2026: 47 · 2025: 61 · 2024: 64 · 2023: 76 · 2022: 79 · 2021: 91 · 2020: 78 · 2019: 60 · 2018: 44 · 2017: 70 · 2016: 66 · 2015: 69 · 2014: 67 · 2013: 52
FWCI: 8.98
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (Z01SC004024)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (ZIAAR041106)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
Keywords: JAK/STAT signaling, cytokine signaling, immunodeficiency, cancer, immune regulation, JAK inhibitors, STAT inhibitors, targeted therapy
MeSH terms: Hematologic Diseases, Humans, Immunologic Deficiency Syndromes, Mutation, Neoplasms, Signal Transduction, Cytokines, STAT Transcription Factors, Janus Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks